FreeTheAI

Prelude Therapeutics Partners with Eli Lilly on Breast Cancer Trial

BullishMedium impact
PRLD$3.74 −3.86%LLY$1,182.62 0.28%

Prelude Therapeutics Incorporated (NASDAQ:PRLD) has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company (NYSE:LLY). Under the deal, Eli Lilly will supply two of its drug candidates, abemaciclib and imlunestrant, to evaluate them in combination with Prelude's experimental compound PRT13722 in patients with HR+/HER2- breast cancer.

PRT13722 is an oral selective degrader targeting KAT6A, an emerging protein target in breast cancer treatment. By pairing PRT13722 with established treatments, Prelude aims to explore whether selective KAT6A degradation can improve efficacy and safety compared to existing dual KAT6A/B inhibitors. Prelude retains all global development and commercial rights to the PRT13722 program.

Following recent U.S. Food and Drug Administration clearance of the Investigational New Drug application for PRT13722, Prelude plans to start enrolling patients in the Phase 1 trial during the fourth quarter of 2026. The study will begin with monotherapy dose escalation before advancing to combination cohorts with Eli Lilly's therapies.

Key points

  • Prelude Therapeutics and Eli Lilly agreed to a clinical trial collaboration for HR+/HER2- breast cancer.
  • Eli Lilly will supply abemaciclib and imlunestrant for use alongside Prelude's drug PRT13722.
  • The U.S. Food and Drug Administration recently cleared PRT13722 for Phase 1 clinical testing.
  • Patient enrollment for the Phase 1 trial is expected to start in the fourth quarter of 2026.
  • Prelude retains full global development and commercial rights to PRT13722.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is the agreement between Prelude Therapeutics and Eli Lilly?

Prelude Therapeutics and Eli Lilly agreed to collaborate on a Phase 1 trial evaluating Prelude's PRT13722 in combination with Lilly's abemaciclib and imlunestrant for HR+/HER2- breast cancer.

When will clinical trial enrollment begin for PRT13722?

Patient enrollment for the Phase 1 clinical trial is expected to begin in the fourth quarter of 2026, starting with monotherapy dose escalation before testing drug combinations.

Does Prelude Therapeutics retain rights to PRT13722?

Yes, Prelude maintains full global development and commercial rights to PRT13722 as a wholly owned program.